Oculis Operations

Oculis Operations Sàrl is a clinical-stage biopharmaceutical company and a wholly-owned subsidiary of Oculis Holding AG, specializing in the development of innovative topical and systemic treatments for ophthalmic and neuro-ophthalmic diseases. The company's pipeline is anchored by three key candidates: OCS-01, a high-concentration topical dexamethasone formulation utilizing the proprietary OPTIREACH solubilizing technology; Licaminlimab (OCS-02), a topical anti-TNFα single-chain antibody fragment for dry eye disease; and Privosegtor (OCS-05), a first-in-class neuroprotective peptoid small molecule targeting acute optic neuritis and other neuropathies. Following the Phase 3 failure of OCS-01 in diabetic macular edema (DME) in mid-2026, Oculis has strategically pivoted its resources to advance Privosegtor in the PIONEER registrational program and Licaminlimab in the genotype-based PREDICT-1 trial. Oculis Operations is headquartered in Lausanne, Switzerland, with global operations spanning the U.S. and Iceland.